Antioxidants play a crucial role in the pharmaceutical industry, preserving the stability and efficacy of drugs by preventing oxidation reactions. Antioxidant 1076, also known as octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate, is one such widely used antioxidant. As a supplier of Antioxidant 1076, I am often asked about its safety assessment in pharmaceuticals. In this blog post, I will delve into the details of the safety evaluation of Antioxidant 1076 in the pharmaceutical context.
Chemical Properties and Mechanism of Action
Antioxidant 1076 is a white crystalline powder with good solubility in organic solvents and low volatility. Its chemical structure contains a phenolic hydroxyl group, which is the key functional group responsible for its antioxidant activity. The mechanism of action of Antioxidant 1076 involves donating a hydrogen atom from the phenolic hydroxyl group to free radicals, thereby neutralizing them and preventing further oxidation reactions. This process helps to protect pharmaceutical ingredients from degradation due to oxidation, such as the oxidation of unsaturated fats, vitamins, and other sensitive compounds.
Regulatory Approval and Compliance
One of the primary indicators of the safety of Antioxidant 1076 in pharmaceuticals is its regulatory approval. Antioxidant 1076 has been approved by major regulatory authorities around the world, including the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory bodies conduct rigorous evaluations of the safety and efficacy of pharmaceutical excipients, including antioxidants, before granting approval for their use in pharmaceutical products.
The approval of Antioxidant 1076 by these regulatory agencies is based on extensive toxicological studies, which assess its potential for acute and chronic toxicity, mutagenicity, carcinogenicity, and reproductive toxicity. These studies have shown that Antioxidant 1076 has a low toxicity profile and is generally considered safe for use in pharmaceuticals within the approved limits.
Toxicological Studies
Numerous toxicological studies have been conducted on Antioxidant 1076 to evaluate its safety. Acute toxicity studies have shown that Antioxidant 1076 has a high LD50 (lethal dose 50), indicating a low acute toxicity. In oral acute toxicity studies in rats, the LD50 of Antioxidant 1076 was found to be greater than 5000 mg/kg body weight, which is considered a very low level of toxicity.
Chronic toxicity studies have also been carried out to assess the long-term effects of Antioxidant 1076. These studies have shown that Antioxidant 1076 does not cause significant adverse effects on the liver, kidneys, or other major organs at doses relevant to its use in pharmaceuticals. In addition, mutagenicity and carcinogenicity studies have indicated that Antioxidant 1076 is not mutagenic or carcinogenic under normal conditions of use.
Comparison with Other Antioxidants
When evaluating the safety of Antioxidant 1076, it is also useful to compare it with other commonly used antioxidants in the pharmaceutical industry. For example, Antioxidant BHT (butylated hydroxytoluene) and Antioxidant 168 (tris(2,4-di-tert-butylphenyl) phosphite) are two other widely used antioxidants. While these antioxidants also have good antioxidant properties, they have some limitations in terms of safety.
Antioxidant BHT has been the subject of some controversy due to its potential for endocrine disruption and other adverse effects. Some studies have suggested that high doses of Antioxidant BHT may have negative impacts on the thyroid gland and reproductive system. In contrast, Antioxidant 1076 has a more favorable safety profile and is considered a safer alternative in many applications.
Antioxidant 168, on the other hand, is a phosphite antioxidant that is mainly used in combination with phenolic antioxidants. While it is generally considered safe, it may have some potential for hydrolysis and degradation, which can lead to the formation of potentially harmful by-products. Antioxidant 1076, being a phenolic antioxidant, is more stable and less prone to such degradation reactions.
Another commonly used antioxidant is Antioxidant DLTP (dilauryl thiodipropionate). It is an organosulfur antioxidant that is effective in preventing the oxidation of polyolefins and other polymers. However, it may have some odor and color issues, which can be a concern in some pharmaceutical applications. Antioxidant 1076, with its low odor and good color stability, is a more suitable choice for pharmaceutical products where these factors are important.
Safety in Different Pharmaceutical Formulations
Antioxidant 1076 can be used in a variety of pharmaceutical formulations, including tablets, capsules, injections, and topical preparations. Its safety has been demonstrated in these different types of formulations.
In tablets and capsules, Antioxidant 1076 helps to protect the active pharmaceutical ingredients (APIs) from oxidation during storage and transportation. It is typically used at low concentrations, usually less than 1% w/w, which is well within the approved safety limits. The presence of Antioxidant 1076 in these formulations does not significantly affect the dissolution and bioavailability of the APIs.
In injections, Antioxidant 1076 can be used to prevent the oxidation of sensitive APIs, such as vitamins and hormones. However, the use of antioxidants in injections requires careful consideration of their compatibility with the formulation and the potential for adverse reactions. Antioxidant 1076 has been shown to be compatible with many injection formulations and does not cause significant irritation or other adverse effects when used at appropriate concentrations.
In topical preparations, Antioxidant 1076 can help to protect the formulation from oxidation and improve its stability. It is also important for maintaining the efficacy of the active ingredients in topical products. The safety of Antioxidant 1076 in topical preparations has been evaluated through skin irritation and sensitization studies, which have shown that it is well-tolerated by the skin and does not cause significant adverse reactions.
Conclusion
In conclusion, Antioxidant 1076 is a safe and effective antioxidant for use in pharmaceuticals. Its regulatory approval, low toxicity profile, and favorable performance in toxicological studies make it a reliable choice for protecting pharmaceutical products from oxidation. Compared to other antioxidants, Antioxidant 1076 offers several advantages in terms of safety and stability.
As a supplier of Antioxidant 1076, I am committed to providing high-quality products that meet the strict safety and quality standards of the pharmaceutical industry. If you are interested in learning more about Antioxidant 1076 or would like to discuss your specific requirements for antioxidant use in pharmaceuticals, please feel free to contact me for a procurement discussion.
References
- FDA. Inactive Ingredient Search for Approved Drug Products. Available at: https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
- EMA. List of excipients with known or suspected genotoxic potential. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/list-excipients-known-suspected-genotoxic-potential_en.pdf
- Toxicological Data for Antioxidant 1076. Various scientific studies and reports from research institutions and pharmaceutical companies.